Elmiron Lawyers

What is Elmiron?

Elmiron (pentosan polysulfate sodium) is a drug approved by the FDA to treat interstitial cystitis—an ailment in the urinary tract that causes abdominal and pelvic pain. The pain can be chronic or intermittent, and the condition can often lead to frequent urination.

Interstitial cystitis is sometimes referred to as bladder pain syndrome and mainly affects women. Elmiron works by attaching itself to the wall of the bladder and providing a buffer between irritating substances and the bladder.

The Problem with Taking Elmiron

Recent studies have shown a strong association between Elmiron use and pigmentary maculopathy—a unique form of retinal eye disease that causes damage to the retina and can often be confused with age-related macular degeneration or pattern dystrophy.

As a result, some medical experts are now recommending that patients using Elmiron have an ophthalmic examination for early detection of maculopathy.

Symptoms of pigmentary maculopathy include the following:

• Blurry Vision
• Night Blindness
• Difficulty Reading
• Dark Spots
• Loss of Close Vision
• Visual Dimming
• Blindness

Why Do I Need an Elmiron Lawyer?

Although there is currently no active Elmiron recall, Meshbesher & Spence is investigating cases of people who took Elmiron for at least one year and were subsequently diagnosed with maculopathy. Therefore, if you experienced any of the symptoms we mentioned and took Elimiron for at least one year, you may be eligible for compensation.

Our law firm has a long history of helping patients injured or harmed by dangerous drugs, such as Elmiron. Furthermore, our team of drug and medical device lawyers profoundly understands the complex legal, medical, and scientific issues related to hazardous pharmaceuticals.

When you hire an attorney from Meshbesher & Spence, you will benefit from our experience and dedication. You will also only pay attorney fees once you receive compensation. That means if you do not recover compensation for your injuries, you pay nothing.